Actively Recruiting
Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes
Led by Umraniye Education and Research Hospital · Updated on 2024-05-16
88
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.
CONDITIONS
Official Title
Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group
- Have a singleton pregnancy
- Did not conceive pregnancy with assisted reproductive treatment methods
- Do not have any pregestational diseases
- Do not have any uterine anomalies
You will not qualify if you...
- Smokers
- Are in the high-risk group with the first trimester screening test
- Have multiple pregnancies
- Conceived with assisted reproductive treatment methods
- Had any disease before pregnancy
- Have any uterine anomalies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ümraniye Eğitim ve Araştırma Hastanesi
Istanbul, Ümraniye, Turkey (Türkiye), 34764
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here